Exophthalmos Treatment Market is expected to grow at a steady 8.2% CAGR, reaching a value of US$ 598 Million by 2033

In fiscal year 2023, the market for exophthalmos treatment is anticipated to be valued US$ 271.8 million, up from US$ 251.2 million in fiscal year 2022. The worldwide market is anticipated to increase steadily between 2023 and 2033, increasing its value to US$ 598 million by the end of that year.

Graves’ illness is most frequently to blame for exophthalmos. Ocular involvement will occur in about 25 to 50 percent of people with this condition. It’s noteworthy to note that ocular dysfunction may occur up to 20 years after the diagnosis of a thyroid problem or up to 10 years before. From 2023 to 2033, these disorders were a key factor in the exophthalmos therapy.

Get Sample Report + Related Graphs & Charts @ https://www.futuremarketinsights.com/reports/sample/rep-gb-16487

A research by Biomed Central Ltd, which was released in September 2020, found that the prevalence of exophthalmos illness patients worldwide was around 10.36% for hypothyroidism, 7.9% for euthyroidism, while 86.2% for hyperthyroidism. As a result, the rising incidence of exophthalmos illness among people is boosting market growth globally and is predicted to do so in the future, propelling the expansion of the studied market throughout the forecast period.

Region-wise, the North American region is expected to be the most lucrative market for exophthalmos diseases. According to figures from the American Academy of Ophthalmology that were published in July 2022, approximately 18 in 100,000 Americans suffer exophthalmos illness. At the same time, novel drug and treatment developments have also been pushing the regional market towards new heights. Such developments are expected to open up new opportunities for the regional manufacturers during the forecast period.

Ask Analyst for Report Customization and Explore TOC & List of Figures @ https://www.futuremarketinsights.com/ask-question/rep-gb-16487

Key Takeaways from the Market Study

• The market for exophthalmos treatment expanded at a CAGR of 6.4% during the historical period of 2018 to 2022.
• The market for exophthalmos treatment is expected to grow steadily from 2023 to 2033, at a 8.2% CAGR.
• It is projected that the non-surgical segment by treatment type will dominate in 2023 with a 53% revenue share.
• With a 25% market share in 2023, the specialty clinic sector by end-user will hold the second-largest segment throughout the projected period.
• From 2023 to 2033, the North American region is expected to expand at a constant CAGR of 8.7%.
• From 2023 to 2033, the Asia Pacific exophthalmos treatment market is anticipated to expand at a stable CAGR of 7.1%.

“The increasing incidences of hyperthyroidism along with Graves’ disease have been accelerating the growth of the global exophthalmos market during the forecast period.” comments a Future Market Insights analyst.

Last few days to get reports at discounted prices, offer expires soon!

Request Discount@ https://www.futuremarketinsights.com/request-discount/rep-gb-16487

Competitive Landscape

Some of the top players in the global exophthalmos disease market are:

• EyeBiotech Ltd.
• Eyevance Pharmaceuticals
• Sling Therapeutics
• Competition Deep Dive
• AbbVie
• Alcon
• Avik Pharma
• Anuh Pharma Ltd.
• Pfizer CentreOne
• Pipelinepharma
• Mylan N.V.
• Manus Aktteva Biopharma LLP
• Roche

Some of the recent developments in this domain are:

• EyeBiotech Ltd., a privately owned ophthalmology biotechnology business seeking to develop a new generation of eye disease therapeutics, announced the successful conclusion of a $65 million Series A fundraising round in 2022. Samsara BioCapital, Jeito Capital, and SV Health Investors spearheaded the round, with additional funding provided by MRL Ventures. A multinational team of executives as well as investors with a long history of creating ground-breaking ophthalmology medicines are brought together for the Series A.

More Insights Available

FMI, in its new offering, presents an unbiased analysis of the global exophthalmos treatment market, presenting historical analysis from 2018 to 2022 and forecast statistics for the period of 2023 to 2033.

The study reveals essential insights on the basis of treatment (non-surgical treatment and surgical treatment), by end-user (hospitals, specialty clinics and others) & region.

Key Segments Covered In The Exophthalmos Treatment Market Report

Exophthalmos Treatment Market By Treatment:

• Non-surgical Treatment
  • Sympathomimetic Amines
  • Corticosteroids
  • Secondary Metabolites
  • Monoclonal Antibodies
  • Radiotherapy
• Surgical Treatment
  • Orbital Decompression
  • Eye Muscle Surgery
  • Eyelid Surgery

Exophthalmos Treatment Market By End User:

• Hospital Pharmacies
• Specialty Clinics
• Others

About FMI:

Future Market Insights, Inc. (ESOMAR certified, Stevie Award – recipient market research organization and a member of Greater New York Chamber of Commerce) provides in-depth insights into governing factors elevating the demand in the market. It discloses opportunities that will favor the market growth in various segments on the basis of Source, Application, Sales Channel and End Use over the next 10-years.

Contact Us:

Future Market Insights Inc.
Christiana Corporate, 200 Continental Drive,
Suite 401, Newark, Delaware – 19713, USA
T: +1-845-579-5705
For Sales Enquiries: sales@futuremarketinsights.com
Website: https://www.futuremarketinsights.com
LinkedIn| Twitter| Blogs